Non-steroidal Anti-Inflammatory Drugs (NSAIDs)

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Outlook

The global Non-steroidal Anti-Inflammatory Drugs (NSAIDs) market is projected to reach approximately USD 39.6 billion by 2035, expanding at a Compound Annual Growth Rate (CAGR) of about 4.5% during the forecast period of 2025-2035. The growth of the NSAIDs market can be attributed to the rising prevalence of chronic pain conditions, the increasing geriatric population, and the growing demand for over-the-counter pain relief medications. Furthermore, advancements in drug formulations and delivery methods, along with increasing awareness about the benefits of NSAIDs, are expected to drive market growth. The ongoing innovations in pharmaceutical research are also contributing to the development of safer and more effective NSAIDs, which will likely boost their adoption in various therapeutic applications. Additionally, the expanding retail and online pharmacy sectors are making NSAIDs more accessible to consumers, thus fueling market expansion.

Growth Factor of the Market

The growth of the NSAIDs market is primarily driven by a combination of demographic, technological, and economic factors. A significant increase in the prevalence of various inflammatory conditions such as arthritis, osteoarthritis, and other musculoskeletal disorders among the aging population is creating a higher demand for effective pain management solutions. Furthermore, the rise in lifestyle diseases, characterized by sedentary habits and poor dietary choices, has contributed to an increase in conditions that require anti-inflammatory treatment. Another critical factor fostering the market's growth is the burgeoning e-commerce sector, which is making NSAIDs more readily available through online pharmacies. This is especially relevant in regions where traditional pharmacies may not be as accessible. Additionally, the focus on developing novel drug formulations, including targeted therapies that minimize gastrointestinal side effects, is encouraging more healthcare providers to prescribe NSAIDs, further enhancing market growth opportunities.

Key Highlights of the Market

• Projected market size of USD 39.6 billion by 2035.
• CAGR of 4.5% anticipated during the forecast period from 2025 to 2035.
• Growing prevalence of chronic pain and inflammatory conditions.
• Increasing consumer awareness regarding OTC medication benefits.
• Advancements in drug formulations leading to safer alternatives.

By Inflammatory Drugs

Aspirin:

Aspirin, one of the oldest NSAIDs, is widely recognized for its anti-inflammatory and analgesic properties. It is commonly used to alleviate pain and reduce inflammation, particularly in conditions such as arthritis and cardiovascular disorders. Aspirin's mechanism of action involves the inhibition of cyclooxygenase (COX) enzymes, which are crucial in the biosynthesis of prostaglandins, responsible for pain and inflammation. The drug's cardiovascular benefits, including reducing the risk of heart attacks and strokes, further add to its market attractiveness. Additionally, aspirin's accessibility and cost-effectiveness make it a popular choice among consumers, which reinforces its strong position in the NSAIDs market.

Ibuprofen:

Ibuprofen is another widely utilized NSAID noted for its efficacy in pain relief and reduction of inflammation. Commonly used for conditions such as headaches, dental pain, and menstrual cramps, ibuprofen is favored for its rapid onset of action and broad safety profile. It is available in various formulations, including tablets, liquids, and topical gels, which enhance its appeal to different patient demographics. The drug's dual mechanism of action, inhibiting both COX-1 and COX-2 enzymes, contributes to its effectiveness. The growing preference for ibuprofen due to its favorable side effect profile compared to traditional NSAIDs bolsters its market share.

Naproxen:

Naproxen is a potent NSAID used primarily for its anti-inflammatory effects in chronic conditions such as arthritis, tendinitis, and gout. It is well-regarded for its long duration of action, often requiring less frequent dosing than other NSAIDs, which can improve patient compliance. The availability of over-the-counter formulations has facilitated its widespread use, making it an accessible option for pain management. Recent studies have also highlighted the potential cardiovascular risks associated with naproxen compared to other NSAIDs, influencing prescriber preferences and market dynamics.

Diclofenac:

Diclofenac is a non-selective NSAID known for its effectiveness in treating moderate to severe pain associated with various inflammatory conditions. Its various formulations, including topical gels, patches, and oral tablets, provide flexibility in administration routes and cater to diverse patient needs. Diclofenac is particularly popular in rheumatology and orthopedics, given its proven efficacy in managing arthritis and post-operative pain. The ongoing research and development aimed at enhancing its therapeutic profiles, such as minimizing gastrointestinal side effects, are likely to foster its continued presence in the market.

Celecoxib:

Celecoxib is a selective COX-2 inhibitor designed to provide pain relief while minimizing gastrointestinal side effects commonly associated with traditional NSAIDs. It is particularly effective for chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis. The drug's selective action allows for targeted relief while maintaining a favorable safety profile, which appeals to patients with a history of gastrointestinal issues. The growing demand for safer pain management alternatives is expected to drive the adoption of celecoxib, supporting its growth within the NSAIDs market.

By Drug Class

Non-Selective NSAIDs:

Non-selective NSAIDs, including drugs like ibuprofen and naproxen, are among the most commonly prescribed medications for pain and inflammation. These drugs are effective in treating a wide range of conditions due to their ability to inhibit both COX-1 and COX-2 enzymes. Non-selective NSAIDs are often utilized in over-the-counter formulations, making them readily accessible to consumers. However, their use is sometimes limited by gastrointestinal side effects, which has led to increased interest in selective COX-2 inhibitors. Nevertheless, non-selective NSAIDs maintain a significant market presence due to their versatility and established efficacy in a variety of therapeutic applications.

Selective COX-2 Inhibitors:

Selective COX-2 inhibitors, such as celecoxib, represent a significant advancement in NSAID therapy, designed to reduce inflammation and pain with fewer gastrointestinal side effects compared to non-selective NSAIDs. These medications are particularly beneficial for patients requiring long-term treatment for chronic conditions, as they provide effective pain relief while minimizing risks. The growing recognition of the importance of patient safety and adherence to medication regimens is likely to drive further adoption of selective COX-2 inhibitors, enhancing their role in the NSAIDs market.

By Route of Administration

Oral:

Oral administration of NSAIDs is the most common route, encompassing tablets, capsules, and liquid formulations. This method offers convenient dosing and widespread availability, making it a preferred option for both patients and healthcare providers. Oral NSAIDs are suitable for various conditions, including pain management, inflammation, and fever reduction. The ease of self-administration and the ability to achieve systemic effects with oral medications contribute to their popularity. However, concerns regarding gastrointestinal side effects and potential interactions with other medications necessitate careful consideration when prescribing and using oral NSAIDs.

Topical:

Topical NSAIDs, delivered through gels, creams, and patches, are designed for localized treatment, providing pain relief directly at the site of application. This route of administration minimizes systemic exposure and associated side effects, making topical NSAIDs a favorable option for individuals with localized pain or inflammation, such as arthritis in the knees or hands. The growing emphasis on patient-centered care and preference for non-invasive treatment options is expected to drive the demand for topical NSAIDs. Furthermore, advancements in formulation technologies are enhancing the efficacy and absorption of topical NSAIDs, further boosting their market presence.

Injection:

Injectable NSAIDs are often used in hospital and clinical settings for rapid pain relief, particularly in acute situations such as post-operative recovery or severe inflammatory conditions. This route of administration allows for precise dosing and quick onset of action, which is critical in managing acute pain scenarios. Injectable formulations are typically administered by healthcare professionals, ensuring safety and efficacy during use. The increasing prevalence of chronic pain and inflammatory diseases is likely to support the continued growth of injectable NSAIDs, although their use remains more limited compared to oral and topical formulations.

By Indication

Pain Management:

Pain management is one of the primary indications for NSAID use, encompassing various conditions from mild headaches to severe postoperative pain. NSAIDs are effective analgesics, providing relief through their anti-inflammatory properties, which aid in reducing pain associated with inflammation. The growing burden of pain-related disorders in the global population, combined with a preference for non-opioid options, supports the sustained demand for NSAIDs in pain management. As patient awareness and acceptance for self-treatment options increase, NSAIDs will continue to play a crucial role in managing both acute and chronic pain.

Inflammation:

NSAIDs are widely utilized for their anti-inflammatory effects, making them essential in treating conditions characterized by inflammation, such as rheumatoid arthritis, osteoarthritis, and tendinitis. The ability of NSAIDs to inhibit the COX enzymes responsible for prostaglandin production allows for effective management of inflammation, leading to improved patient outcomes. The rising incidence of inflammatory disorders is expected to bolster the demand for NSAIDs in this indication, as healthcare professionals seek effective treatment options to enhance quality of life for affected individuals. Continuous advancements in NSAID formulations are likely to further optimize their use in managing inflammation.

Fever:

Fever management is another critical indication for NSAID use, particularly in pediatric and adult populations. NSAIDs like ibuprofen and aspirin are commonly employed to reduce fever due to their antipyretic properties. The ease of accessibility and over-the-counter availability of these medications make them the go-to choice for fever management in households. The increasing prevalence of infectious diseases and viral outbreaks necessitates effective fever reduction strategies, thereby sustaining market demand for NSAIDs designated for this indication. Education regarding appropriate dosing and safety in using NSAIDs for fever will be crucial in maintaining their positive market trajectory.

Arthritis:

NSAIDs play a pivotal role in the management of arthritis, a leading cause of disability worldwide. Both rheumatoid arthritis and osteoarthritis patients commonly rely on NSAIDs to alleviate pain and reduce joint inflammation. The effectiveness of NSAIDs in improving joint mobility and enhancing the overall quality of life for arthritis patients reinforces their importance in treatment regimens. The aging population, particularly those aged 65 and older, faces an increasing prevalence of arthritis, driving demand for effective NSAID therapies. Innovative research focusing on developing specialized NSAIDs with reduced side effects will support continued growth in this segment.

Menstrual Cramps:

NSAIDs are frequently employed in managing menstrual cramps, providing relief for many individuals experiencing dysmenorrhea. Medications such as ibuprofen are particularly effective due to their ability to reduce uterine contractions and alleviate pain. As awareness of menstrual health and the availability of effective pain management options grows, NSAIDs gain popularity among individuals seeking reliable solutions for menstrual discomfort. The emphasis on empowering women to manage their menstrual health proactively contributes to the ongoing demand for NSAIDs in this indication.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies serve as a critical distribution channel for NSAIDs, particularly for prescription medications dispensed in clinical settings. NSAIDs are frequently used in hospitals for managing acute pain and inflammation, making them an essential component of hospital formularies. Pharmacists play a vital role in ensuring appropriate NSAID use, providing guidance on dosing, potential interactions, and monitoring for side effects. The increasing demand for effective pain management solutions in hospitals, combined with an emphasis on patient safety, is expected to support growth in this distribution channel.

Retail Pharmacies:

Retail pharmacies are a primary distribution channel for over-the-counter NSAIDs, offering a wide range of products accessible to consumers without a prescription. The convenience and immediacy of purchasing NSAIDs from local pharmacies make them a popular choice for individuals seeking relief from pain and inflammation. The competitive landscape among retail pharmacies, including promotional offers and brand loyalty programs, influences consumer purchasing decisions and drives market dynamics. The future growth of retail pharmacies as distribution channels for NSAIDs will be supported by continued consumer education and awareness of self-treatment options.

Online Pharmacies:

Online pharmacies have emerged as a significant distribution channel for NSAIDs, especially in light of the increasing trend toward e-commerce and digital health solutions. The convenience of purchasing medications online, coupled with the discretion it offers patients, is driving the growth of this distribution channel. Additionally, the global pandemic has accelerated the adoption of online pharmacy services, allowing consumers to access NSAIDs without the need for in-person visits. However, the rise of online pharmacies also necessitates strict regulations to ensure safety and quality, as well as to combat counterfeit medications. Overall, the trend toward digital health is likely to enhance the prominence of online pharmacies in the NSAIDs market.

By Region

The North American NSAIDs market is expected to dominate the global landscape, projected to achieve a market share of approximately USD 14 billion by 2035, growing at a CAGR of 4.2%. The high prevalence of chronic pain conditions, coupled with a well-established healthcare infrastructure and increased awareness about pain management options, drive the demand for NSAIDs in this region. Additionally, the availability of a wide range of over-the-counter and prescription NSAIDs further solidifies North America's leading position in the global market. The increasing adoption of innovative drug formulations and delivery systems is anticipated to enhance market dynamics, contributing to sustained growth in the region.

In the European market, NSAIDs are also witnessing substantial growth, with a projected market size of around USD 12 billion by 2035. The rise in the geriatric population and the prevalence of inflammatory diseases are significant factors propelling the demand for NSAIDs in Europe. The region is characterized by a strong focus on patient education and awareness regarding the safe use of NSAIDs, which is expected to positively influence market dynamics. Furthermore, the presence of major pharmaceutical companies engaged in the development of novel NSAID formulations is likely to enhance competition and expand the market in Europe, contributing to overall regional growth.

Opportunities

The NSAIDs market is rife with opportunities, particularly in the context of increasing investments in research and development aimed at creating safer and more effective pain management solutions. Innovations in drug formulation technologies, including the development of novel delivery systems that enhance bioavailability and minimize gastrointestinal side effects, are expected to attract significant interest from both pharmaceutical companies and healthcare providers. The growing emphasis on personalized medicine offers a unique opportunity to develop NSAIDs tailored to individual patient needs, which could enhance treatment efficacy and foster greater patient compliance. Additionally, the expansion of telemedicine and digital health solutions presents an opportunity to improve access to NSAIDs, particularly in underserved regions, leading to improved healthcare outcomes and increased market penetration.

Moreover, the growing awareness about the importance of self-management and preventive healthcare presents a significant opportunity for the NSAIDs market. As consumers increasingly seek out over-the-counter medications for pain relief and inflammation, there is potential for NSAIDs to capture a larger share of the self-care market. The development of educational campaigns aimed at informing consumers about the proper use of NSAIDs can drive further acceptance and utilization of these medications. Additionally, partnerships between pharmaceutical companies and online retailers can enhance distribution networks, making NSAIDs more accessible to patients. Overall, the convergence of technological advancements, consumer preferences, and healthcare initiatives creates a myriad of opportunities for growth within the NSAIDs market.

Threats

Despite the growth potential, the NSAIDs market faces several threats that could impede its progress. One significant concern is the rising awareness of the safety profiles associated with NSAID use, particularly regarding gastrointestinal, cardiovascular, and renal risks. Increased scrutiny from regulatory bodies and the demand for stringent labeling and risk communication could potentially limit the prescription and over-the-counter sale of certain NSAIDs. Additionally, the evolving landscape of pain management presents competition from alternative therapies, including non-pharmacological treatments such as physical therapy, acupuncture, and nutritional approaches, which may sway patients away from NSAID use. The emergence of newer classes of pain management drugs, including biologics and opioid-sparing alternatives, presents a challenge that could impact the NSAIDs market share significantly.

Furthermore, the global supply chain disruptions witnessed during the recent pandemic highlighted vulnerabilities in the pharmaceutical industry, including the production and distribution of NSAIDs. Any potential future disruptions could lead to shortages, impacting availability and market dynamics. The increasing prevalence of counterfeit medications distributed through online channels also poses a significant risk to patient safety and brand integrity, which could further complicate the market landscape. Companies must remain vigilant in addressing these threats through proactive measures, including improved product tracking and consumer education about sourcing medications from reputable distributors.

Competitor Outlook

• Pfizer Inc.
• Bristol-Myers Squibb
• Johnson & Johnson
• Novartis AG
• GlaxoSmithKline plc
• Roche Holding AG
• Sanofi S.A.
• AstraZeneca plc
• AbbVie Inc.
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• Mylan N.V.
• Endo International plc
• Amgen Inc.

The competitive landscape of the NSAIDs market is characterized by both established pharmaceutical giants and emerging companies striving to capture market share through innovation and strategic collaborations. Major players like Pfizer Inc. and Bristol-Myers Squibb have made significant investments in research and development to enhance their NSAID offerings. These companies leverage their extensive product portfolios to address the diverse needs of patients, thus solidifying their positions in the market. Additionally, collaborations with healthcare providers and advocacy groups are increasingly important for these companies to enhance awareness and education around the safe use of NSAIDs.

Moreover, the presence of generic manufacturers is intensifying competition within the NSAIDs market, as generic options often provide cost-effective alternatives to branded medications. Companies like Teva Pharmaceutical Industries and Mylan N.V. are well-positioned to capitalize on the demand for affordable NSAID options, catering to cost-sensitive consumers. As generics continue to gain traction, established players must adapt their strategies to maintain competitiveness, which may include price adjustments and enhanced marketing efforts. The focus on patient-centric approaches and personalized medicine is also a growing trend among competitors, with many companies striving to develop tailored NSAID therapies that align with individual patient needs.

As the market evolves, companies are investing in technological advancements such as digital health solutions, telemedicine, and online pharmacy partnerships to enhance patient engagement and medication adherence. This digital transformation is reshaping the way NSAIDs are marketed and distributed, presenting both opportunities and challenges for stakeholders in the market. By embracing innovative strategies and fostering collaborations, major companies are positioning themselves for long-term growth and sustainability in the competitive NSAIDs market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Mylan N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AstraZeneca plc
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Holding AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Johnson & Johnson
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Merck & Co., Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 GlaxoSmithKline plc
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bristol-Myers Squibb
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Endo International plc
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Hikma Pharmaceuticals PLC
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market, By Drug Class
    • 6.1.1 Aspirin
    • 6.1.2 Ibuprofen
    • 6.1.3 Naproxen
    • 6.1.4 Diclofenac
    • 6.1.5 Celecoxib
  • 6.2 Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market, By Indication
    • 6.2.1 Pain Management
    • 6.2.2 Inflammation
    • 6.2.3 Fever
    • 6.2.4 Arthritis
    • 6.2.5 Menstrual Cramps
  • 6.3 Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market, By Distribution Channel
    • 6.3.1 Hospital Pharmacies
    • 6.3.2 Retail Pharmacies
    • 6.3.3 Online Pharmacies
  • 6.4 Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market, By Route of Administration
    • 6.4.1 Oral
    • 6.4.2 Topical
    • 6.4.3 Injection

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Non-steroidal Anti-Inflammatory Drugs (NSAIDs) market is categorized based on

By Drug Class

• Aspirin
• Ibuprofen
• Naproxen
• Diclofenac
• Celecoxib

By Route of Administration

• Oral
• Topical
• Injection

By Indication

• Pain Management
• Inflammation
• Fever
• Arthritis
• Menstrual Cramps

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• Bristol-Myers Squibb
• Johnson & Johnson
• Novartis AG
• GlaxoSmithKline plc
• Roche Holding AG
• Sanofi S.A.
• AstraZeneca plc
• AbbVie Inc.
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• Mylan N.V.
• Endo International plc
• Amgen Inc.